By Finance Pulse in NVO —

Novo Nordisk Shares Plunge 21% After Drug Trial Disappointment

Novo Nordisk shares tumble 21% after CagriSema trial results miss expectations, sparking retail investor interest. Discover the implications for NVO stock.

Illustration of a downward-trending stock chart with Novo Nordisk logo, symbolizing financial declin
Novo Nordisk Shares Plunge 21% After Drug Trial Disappointment

Novo Nordisk's shares dropped significantly after disappointing drug trial results.

Source